Atlas-backed Diagonal Therapeutics launches with $128M
The Cambridge biotech is working on new ways to discover and develop “agonist antibodies,” and its Series A round was co-led by Atlas Venture and BVF Partners.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Hannah Green Source Type: news
More News: Biotechnology | Health Management